We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Pharmacokinetic Study of TV-44749 Extended-release in Participants with Schizophrenia

- Schizophrenia, Schizoaffective Disorder
- Recruiting

Study Title: A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the pharmacokinetics of three SC Olanzapine Extended-Release Formulations with Different Release Rates Following Single Administration in Participants with Schizophrenia or Schizoaffective Disorder

Teva Identifier: TV44749-NPC-10205

ClinicalTrials.gov Identifier: NCT06319170

Study Status: Recruiting

Trial Condition(s): Schizophrenia, Schizoaffective Disorder

Interventions: Drug: TV-44749

Study Description: The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years to 64 Years

Trial Duration: March 28, 2024 - December 11, 2024

Phase: Phase 1

Study Type

Interventional